{PDOC51135} {PS51135; CIDE_N} {BEGIN} ************************* * CIDE-N domain profile * ************************* The CIDE-N or CAD domain is a ~78 amino acid protein-protein interaction domain in the N-terminal part of Cell death-Inducing DFF45-like Effector (CIDE) proteins, involved in apoptosis. At the final stage of programmed cell death, chromosomal DNA is degraded into fragments by Caspase-activated DNase (CAD), also named DNA fragmentation factor 40 kDa (DFF40). In normal cells CAD/DFF40 is completely inhibited by its binding to DFF45 or Inhibitor of CAD (ICAD). Apoptotic stimuli provoke cleavage of ICAD/DFF45 by caspases, resulting in self-assembly of CAD/DFF40 into the active dimer [1]. Both CAD/DFF40 and ICAD/DFF45 possess an N-terminal CIDE-N domain that is involved in their interaction. The name of the CIDE-N domain refers to the CIDE proteins and CAD, where the domain forms the N-terminal part [2,3]. The CIDE-N domains from different proteins can interact, e.g. CIDE-N of CIDE-B and ICAD/DFF45 with CIDE-N of CAD/DFF40, and such interactions can also be needed for proper folding [4,5]. Tertiary structures show that the CIDE-N domain forms an alpha/beta roll fold of five beta-strands forming a single, mixed parallel/anti-parallel beta-sheet with one [4] or two [3,5] alpha-helices packed against the sheet (see ). Binding surfaces of the CIDE-N domain form a central hydrophobic cluster, while specific binding interfaces can be formed by charged patches. Some proteins known to contain a CIDE-N domain: - Mammalian DNA fragmentation factor 40 kDa (DFF40) or Caspase-activated deoxyribonuclease (CAD), an endonuclease that induces DNA fragmentation and chromatin condensation during apoptosis. The degradation of chromosomal DNA by CAD/DFF40 will kill the cells. - Mammalian DNA fragmentation factor 45 kDa (DFF45) or Inhibitor of CAD (ICAD), which controls the activity and proper folding of CAD/DFF40. - Mammalian CIDE-A and CIDE-B, activators of cell death and DNA fragmentation that can be inhibited by ICAD/DFF45. In contrast with CAD and ICAD, the CIDE proteins are expressed in a highly restricted way and show pronounced tissue specificity. - Fruit fly DNAation factor DREP1, a DFF45 homolog that can inhibit CIDE-A-induced apoptosis. The profile we developed covers the entire CIDE-N domain. -Sequences known to belong to this class detected by the profile: ALL. -Other sequence(s) detected in Swiss-Prot: NONE. -Last update: June 2005 / First entry. [ 1] Woo E.J., Kim Y.G., Kim M.S., Han W.D., Shin S., Robinson H., Park S.Y., Oh B.H. "Structural mechanism for inactivation and activation of CAD/DFF40 in the apoptotic pathway." Mol. Cell 14:531-539(2004). PubMed=15149602 [ 2] Inohara N., Koseki T., Chen S., Wu X., Nunez G. "CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor." EMBO J. 17:2526-2533(1998). PubMed=9564035; DOI=10.1093/emboj/17.9.2526 [ 3] Lugovskoy A.A., Zhou P., Chou J.J., McCarty J.S., Li P., Wagner G. "Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis." Cell 99:747-755(1999). PubMed=10619428 [ 4] Uegaki K., Otomo T., Sakahira H., Shimizu M., Yumoto N., Kyogoku Y., Nagata S., Yamazaki T. "Structure of the CAD domain of caspase-activated DNase and interaction with the CAD domain of its inhibitor." J. Mol. Biol. 297:1121-1128(2000). PubMed=10764577; DOI=10.1006/jmbi.2000.3643 [ 5] Zhou P., Lugovskoy A.A., McCarty J.S., Li P., Wagner G. "Solution structure of DFF40 and DFF45 N-terminal domain complex and mutual chaperone activity of DFF40 and DFF45." Proc. Natl. Acad. Sci. U.S.A. 98:6051-6055(2001). PubMed=11371636; DOI=10.1073/pnas.111145098 -------------------------------------------------------------------------------- PROSITE is copyrighted by the SIB Swiss Institute of Bioinformatics and distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND 4.0) License, see https://prosite.expasy.org/prosite_license.html -------------------------------------------------------------------------------- {END}